

Clinical trial results:

Phase II, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor

Summary	
Results information	
Trial information	
Trial identification	
Additional study identifiers	
Sponsors	
Paediatric regulatory details	

Results analysis stage	
General information about the tri	ial
Population of trial subjects	
Subjects enrolled per country	
Subjects enrolled per age group	

Subject disposition	
Recruitment	
Pre-assignment	
Period 1	
Arms	
Arm title	
Number of subjects in period 1	
	1
	-

Reporting groups Reporting group values


Baseline characteristics

nd points reporting grou	ps			
rimary: Percentage of Su CR]/Partial Response [Pl esonance Imaging (MRI) umors (RECIST) Version	R]) Based on C According to	omputer Tom	nography (CT	or Magnetic
	•			
nd naint values				
nd point values				
	!	ļ.	!	
Statistical analyses				
Secondary: Progression Fi RECIST v 1.1	ee Survival (P	FS) Based on	CT or MRI Ad	cording to
	ļ.			


d point values					
	,		!		,
atistical analyses					
acandamy Daycontago of	Cubicata :	with Enida	was Crawth	Factor Bases	tor (ECED)
econdary: Percentage of utation in Study Populati	Subjects vion	with Epiae	ermai Growth	ractor Recep	otor (EGFR
	ļ				
	'				
nd noint values					
nd point values					
nd point values					
nd point values					
nd point values					
nd point values					
nd point values					
nd point values					
nd point values					

	ı		
	l		
	ı		
End point values			
point values			
Statistical analyses			

Adverse events Adverse events information Dictionary used Reporting groups Serious adverse events



Non-serious adverse events		



More information

Substantial protocol amendments (globally)

Date	Amendment

Interruptions (globally)

Limitations and caveats